[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:partner-and-localizer-of-brca2":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Partner and Localizer of BRCA2",43,36,[8,16,23,29,36,42,48,54,60,66,72,79,85,91,97,102,108,115,121,127,133,139,145,151,156,162,168,174,180,186,192,198,204,210,216,222,228,235,241,247,254,261,267],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06844383","A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate",[12],"Phase 2","RECRUITING","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.708217Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04150042","SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells",[20],"Phase 1","2026-08-26T02:18:58.141497Z","2026-05-05T02:43:29.297862Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04858334","APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",[12],"2026-08-26T02:15:52.238965Z","2026-05-05T02:43:29.056915Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06380751","Saruparib (AZD5305) Plus Camizestrant Compared With CDK4\u002F6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+\u002F ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",[33],"Phase 3","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.920406Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[20],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06177171","Olaparib and ASTX727 in BRCA1\u002F2- and Homologous Recombination Deficient (HRD)-Mutated Tumors",[20],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:27.676733Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06488378","Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1\u002F2 and PALB2- Associated Metastatic HER2-negative Breast Cancer",[20],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.482798Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[12],"2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05694715","Combination Therapy in Cancers With Mutations in DNA Repair Genes",[20],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:28.876459Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06458712","Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",[20],"2026-08-26T02:15:51.395565Z","2026-07-24T01:27:14.872137Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":77,"content_modified":78},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[76],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04890613","Study of CX-5461 in Patients With Solid Tumours and BRCA1\u002F2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",[20],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:27.067991Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05287451","Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study",[],"2026-08-26T02:15:44.309045Z","2026-07-05T05:32:16.798306Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05013216","Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",[20],"2026-08-26T02:16:23.080181Z","2026-05-05T02:43:26.738998Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":83,"content_modified":101},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[12],"2026-07-19T19:36:05.126907Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[12],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:26.724920Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":113,"content_modified":114},"NCT06122896","Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals",[112],"Early Phase 1","2026-08-26T02:17:13.277148Z","2026-05-05T02:43:27.075591Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT03729115","A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer",[],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:26.901351Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT02000089","The Cancer of the Pancreas Screening-5 CAPS5)Study",[33],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.641158Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07612046","A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening",[],"2026-08-26T02:16:27.227548Z","2026-07-19T19:36:05.076756Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT03396341","Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes",[],"2026-08-26T02:16:12.203827Z","2026-07-05T05:32:16.770025Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:16:05.813655Z","2026-06-14T18:39:22.265063Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT07038785","Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.608906Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":40,"content_modified":155},"NCT06888388","Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer",[],"2026-05-13T02:55:06.588403Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06271291","Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts",[],"2026-08-26T02:18:36.226508Z","2026-05-13T02:55:06.430707Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.292506Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT05058846","Pilot Study of Pancreatic Cancer Screening",[],"2026-08-03T02:54:15.542480Z","2026-05-13T02:55:06.282505Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT05006131","Pancreatic Cancer Screening for At-risk Individuals",[],"2026-08-26T02:17:12.307088Z","2026-05-13T02:55:06.277680Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT04706663","Precision-Based Genomics in Prostate Cancer",[],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.268346Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT03805919","Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:15:18.897219Z","2026-05-13T02:55:06.177945Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT03250078","A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals",[],"2026-08-26T02:16:58.658552Z","2026-05-13T02:55:06.120432Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT02478892","Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk",[],"2026-08-26T02:19:21.761002Z","2026-05-13T02:55:06.095979Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT02302742","Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry",[],"2026-08-26T02:17:28.381459Z","2026-05-13T02:55:06.091980Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT04970056","Pancreatic Cancer Early Detection Consortium",[],"2026-08-26T02:15:04.877798Z","2026-05-13T02:55:06.276618Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT02775461","Pancreas Registry and High Risk Registry",[],"2026-08-26T02:15:27.567165Z","2026-05-13T02:55:06.101947Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT04038502","Carboplatin or Olaparib for BRcA Deficient Prostate Cancer",[12],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.505079Z",{"nct_id":229,"title":230,"phases":231,"status":232,"updated_at":233,"content_modified":234},"NCT07565155","Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:15.642947Z","2026-05-13T02:55:06.729176Z",{"nct_id":236,"title":237,"phases":238,"status":232,"updated_at":239,"content_modified":240},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[12],"2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":242,"title":243,"phases":244,"status":232,"updated_at":245,"content_modified":246},"NCT07690852","Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care",[],"2026-08-26T02:16:24.970704Z","2026-07-19T19:36:05.153122Z",{"nct_id":248,"title":249,"phases":250,"status":251,"updated_at":252,"content_modified":253},"NCT07358208","Prospective Familial Registry for Pancreas Research",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:26.493949Z","2026-06-16T05:54:07.881076Z",{"nct_id":255,"title":256,"phases":257,"status":258,"updated_at":259,"content_modified":260},"NCT06212583","High-Risk Metachronous Oligometastatic Prostate Cancer Trial",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:25:31.771325Z","2026-05-05T02:43:29.167176Z",{"nct_id":262,"title":263,"phases":264,"status":258,"updated_at":265,"content_modified":266},"NCT05498272","Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",[12],"2026-08-03T02:05:27.322885Z","2026-05-05T02:43:27.674415Z",{"nct_id":268,"title":269,"phases":270,"status":258,"updated_at":271,"content_modified":272},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[12],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]